Jose Pando, MD
Rheumatology · Lewes, DENPI 1306839048
Payments from drug & device makers
Across 1,106 payments — averaging $303.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$137K
- Eli Lilly$74K
- Pfizer$33K
- Sanofi$24K
- Lilly USA, LLC$12K
- Dr.reddy's Laboratories,inc.$9K
- plus $46K from 31 others
Across 1 payment — averaging $15.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15
What the payments were for
- Consulting fees$19,05421%
- Speaking & faculty fees$40,28943%
- Grants$2400%
- Travel & lodging$8,3709%
- Food & beverage$24,42826%
- Education$3460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 196 | $136,786 |
| Eli Lilly | 11 | $73,849 |
| Pfizer | 87 | $33,447 |
| Sanofi | 61 | $23,874 |
| Lilly USA, LLC | 73 | $12,366 |
| Dr.reddy's Laboratories,inc. | 3 | $9,000 |
| Regeneron Healthcare Solutions, Inc. | 14 | $8,768 |
| Sanofi US Services Inc. | 13 | $8,165 |
| E.r. Squibb & Sons, L.L.C. | 33 | $7,011 |
| Novartis | 44 | $6,265 |
| Amgen(2 entities) | 134 | $3,743 |
| Johnson & Johnson(3 entities) | 100 | $2,991 |
| UCB, Inc. | 102 | $2,328 |
| Mallinckrodt Hospital Products Inc. | 49 | $1,735 |
| AstraZeneca(2 entities) | 54 | $1,044 |
| Radius Health, Inc. | 24 | $693 |
| Aurinia Pharma U.S., Inc. | 7 | $371 |
| Janssen Scientific Affairs, LLC | 3 | $323 |
| ANI Pharmaceuticals, Inc. | 12 | $311 |
| Progentec Diagnostics, Inc. | 2 | $298 |
| GSK | 14 | $287 |
| Pacira Therapeutics, Inc. | 7 | $272 |
| Organon | 13 | $263 |
| Genentech USA, Inc. | 8 | $259 |
| Mallinckrodt Enterprises LLC | 9 | $188 |
| Boehringer Ingelheim | 6 | $159 |
| Fresenius Kabi USA, LLC | 6 | $126 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Sandoz | 5 | $96 |
| Bristol Myers Squibb | 4 | $93 |
| Eisai Inc. | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Merck | 2 | $29 |
| Medexus Pharma, Inc. | 2 | $28 |
| Alvogen Inc | 1 | $25 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Orthogenrx Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few rheumatology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 134 | $1,292,439 |
| ActharCorticotropin | 13 | $602,440 |
| Xeljanz XrTofacitinib Citrate | 40 | $382,116 |
| Humira(Cf) PenAdalimumab | 19 | $319,450 |
| Humira PenAdalimumab | 17 | $210,665 |
| Orencia ClickjectAbatacept | 23 | $210,588 |
| RinvoqUpadacitinib | 19 | $201,422 |
| SimponiGolimumab | 19 | $162,720 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $160,034 |
| KevzaraSarilumab | 26 | $127,796 |
| EnbrelEtanercept | 15 | $111,504 |
| Teriparatide | 19 | $91,834 |
| BenlystaBelimumab | 12 | $58,048 |
| Hydroxychloroquine Sulfate | 595 | $37,118 |
| ActemraTocilizumab | 11 | $28,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $1,735 | $602,44013 claims |
| AbbVieRinvoq | $136,786 | $201,42219 claims |
| Johnson & JohnsonSimponi | $2,991 | $162,72019 claims |
| SanofiKevzara | $23,874 | $127,79626 claims |
| AmgenEnbrel | $3,743 | $111,50415 claims |
| Alvogen IncTeriparatide | $25 | $91,83419 claims |
| GSKBenlysta | $287 | $58,04812 claims |
| Dr.reddy's Laboratories,inc.Pregabalin | $9,000 | $79833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other rheumatology in Lewes
- Lourdes AponteLewes$20K
- Sheerin JavedNewark$13K
- Jinsong ZhangDover$11K
- Philip SchwartzWilmington$10K
- Ivonne HerreraSeaford$9K
- Amy ZhangNewark$8K
- Surjeet DheerDover$7K
- Yvan Maque AcostaDover$5K
- Robert MoyerDover$3K
- Shakaib QureshiWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.